Home Archive
Archive
2024 Volume 45 Issue 7  Published: 2024-07-10
    Topic
  • Cong RUAN , Jiajia QIAN , Qiong DU , Qing ZHAI , Xiaomin SUN , Rui XU
    doi: 10.13683/j.wph.2024.07.001

    All-trans-retinoic acid (ATRA) is the clinical choice for the treatment of acute promyelocytic leukemia. However, in recent years, a large number of studies have shown that ATRA maintains the human normal immune microenvironment by inhibiting the immune escape effect of tumor stem cells and promoting the differentiation of myeloid-derived suppressor cells, and enhances the efficacy of chemotherapeutic drugs, targeted drugs and immunotherapy drugs in solid tumors. This paper reviewed the clinical trial progress of ATRA in solid tumors to provide a reference for its further clinical application.

  • Topic
  • Jiayan FAN , Shuohan HUANG , Yanchun MENG , Qiong DU , Jiyong LIU , Qing ZHAI
    doi: 10.13683/j.wph.2024.07.002

    Triple-negative breast cancer (TNBC) is aggressive, prone to recurrence and metastasis. There is a higher risk of early recurrence and a worse prognosis compared to other types of breast cancer. Due to the lack of specific therapeutic targets, the first-line treatment recommendations for metastatic TNBC (mTNBC) in China are still mainly based on anthracycline or paclitaxel as monotherapy or combination chemotherapy. In recent years, with the successful application of new therapeutic drugs in mTNBC, some new drugs have been approved for the treatment of mTNBC abroad. This article reviewed the recent advances in mTNBC molecular typing, immunity and antibody drug conjugations.

  • Topic
  • Rui XU , Jiajia QIAN , Cong RUAN , Qiru WANG , Qing ZHAI
    doi: 10.13683/j.wph.2024.07.003

    Angiogenesis plays a key role in the growth, local invasion and distant metastasis of a variety of solid tumors. At present, anti-angiogenesis drugs can be divided into three types: small-molecule multi-target, macromolecule single-target and endogenous pan-target angiogenesis inhibitors. Among them, small molecule anti-angiogenesis inhibitors mainly inhibit tumor angiogenesis by simultaneously or sequentially targeting multiple growth factors/pathways, and can effectively inhibit drug resistance generated by tumor cells. At the same time, small molecule anti-angiogenesis inhibitors have the advantages of good tissue permeability and convenient administration. At present, it has been widely used in the combination therapy of various solid tumors. This paper reviewed the targeted therapy of small molecule anti-angiogenic tyrosine kinase inhibitors and their clinical progress and safety in multiple solid tumors.

  • Article
  • Jiangtao GUO , Kaixuan REN , Yumin XIA
    doi: 10.13683/j.wph.2024.07.004
    Objective

    To explore the effects of Banzhilian formula on the expression levels of tumor necrosis factor-like weak inducer of apoptosis (TWEAK), fibroblast growth factor-inducible (Fn)-14, and lipocalin (Lcn)-2 in the psoriatic mouse skin tissue induced by imiquimod, and to investigate the mechanism of action.

    Method

    A total of 21 BALB/c male mice were randomly divided into control group, model group and intervention group, with 7 mice in each group. The control group was given Vaseline and 0.9% sodium chloride injection intragastric administration, the model group was given imiquimod and 0.9% sodium chloride injection intragastric administration, and the intervention group was given imiquimod and Banzhilian formula intragastric administration for 7 consecutive days. The psoriasis area and severity index (PASI) scores in each group were compared. Hematoxylin eosin staining was used to observe the pathological changes of skin tissue. The expressions of Ki-67, Fn-14 and Lcn-2 in skin lesions were detected by immunohistochemistry. The levels of Fn-14 and Lcn-2 in skin lesions were detected by western blot. TWEAK content in skin lesions was determined by enzyme linked immunosorbent assay. The mRNA expression of TWEAK, Fn-14 and Lcn-2 were detected by quantitative polymerase chain reaction.

    Results

    Compared with the model group, the severity of skin erythema and scales in the intervention group were reduced, PASI score and the number of Ki-67 positive cells were decreased, the mRNA and protein expression of TWEAK, Fn-14, and Lcn-2 in the lesion tissues were significant decreased (P<0.05).

    Conclusion

    Banzhilian formula can improve imiquimod-induced skin inflammatory response in mouse psoriasis model, possibly by inhibiting TWEAK/Fn-14 signaling pathway.

  • Article
  • Xing GAO , Ling ZHAO , Ling HU , Xuefei YONG , Lin ZHOU
    doi: 10.13683/j.wph.2024.07.005
    Objective

    To explore the clinical efficacy of candesartan combined with amlodipine on essential hypertension (EH).

    Methods

    A total of 120 EH patients admitted to our hospital from February 2022 to January 2023 were selected and divided into observation group (amlodipine+candesartan) and control group (amlodipine) according to random number table method, with 60 cases in each group. The course of treatment for all patients was 8 weeks. The efficacy, ambulatory blood pressure [coefficient of variation in daytime systolic blood pressure (SCV), coefficient of variation in nocturnal systolic blood pressure (nSCV), coefficient of variation of 24-hour systolic blood pressure (24hSCV), coefficient of variation in daytime diastolic blood pressure (DCV), coefficient of variation in nocturnal diastolic blood pressure (nDCV), coefficient of variation of 24-hour diastolic blood pressure (24hDCV)], carotid intimal medial thickness (IMT), stromal interaction molecule (STIM)1 and occurrence of adverse reactions of the two groups were compared between the two groups.

    Results

    After treatment, the total clinical effective rate of the observation group was higher than that of the control group (98.33% vs 80.00%), the difference was statistically significant (P<0.05). SCV, nSCV, 24hSCV, DCV, nDCV, 24hDCV, IMT and STIM1 were all decreased in both groups, and the observation group was lower than the control group (P<0.05). The incidence of adverse reactions was 3.34% in both groups, with no statistical significance (P>0.05).

    Conclusion

    Candesartan combined with amlodipine can effectively reduce blood pressure variability, IMT and STIM1 levels in EH patients, improve prognosis and clinical efficacy.

  • Article
  • Jianhui GUO , Wen GUO , Kaiqing DU , Ke GONG , Ya'na SHEN
    doi: 10.13683/j.wph.2024.07.006
    Objective

    To observe the clinical efficacy of Molian Qubai decoction combined with 308 nm excimer laser in treating vitiligo of kidney deficiency and blood stasis type.

    Methods

    A total of 86 patients with vitiligo of kidney deficiency and blood stasis type were divided into control group and study group by simple ranking random scheme and the random number table method, with 43 cases in each group. The control group received 308 nm excimer laser, and the study group received Molian Qubai decoction combined with 308 nm excimer laser. The efficacy, white spot area, white spot resolution time, immunoglobulin (Ig) G, IgM, IgA, serum complement hemolytic activity (CH50), T lymphocyte subpopulations, and adverse reactions in the two groups were compared.

    Results

    The total effective rate of the study group was higher than that of the control group (90.70% vs 72.09%, P<0.05). After treatment, the vitiligo area score index, and the levels of IgG, IgM, and IgA in both groups were lower than before treatment (P<0.05), and the study group were lower than the control group (P<0.05). The time for white spot regression in the study group was earlier than that in the control group (P<0.05). After treatment, the levels of CH50, CD3+, CD4+, CD4+/CD8+ in both groups were higher than before treatment (P<0.05), and the study group was higher than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    The combination of Molian Qubai decoction and 308 nm excimer laser can enhance the immune function of patients with vitiligo of kidney deficiency and blood stasis type, reduce the area of white spots, accelerate the resolution of white spots, improve the therapeutic effect, and do not increase adverse reactions.

  • Article
  • Mei HUANG , Lina CUI , Liping LIU
    doi: 10.13683/j.wph.2024.07.007
    Objective

    To investigate the effect of Yiyuan Qingfei decoction combined with etemicin on patients with severe pneumonia of Qi deficiency lung heat syndrome, and its effects on serum amyloid (SA) A, cholinesterase (ChE), chitinase 3-like protein (CHI3L)1 levels.

    Methods

    A total of 100 cases of severe pneumonia of Qi deficiency lung heat syndrome in our hospital from January 2019 to June 2022 were selected and divided into control group and observation group by drawing lots method, with 50 cases in each group. The control group was treated with etimicin, and the observation group was treated with Yiyuan Qingfei decoction on the basis of the control group. The course of treatment was 2 weeks. The efficacy, clinical symptoms, traditional Chinese medicine (TCM) syndrome scores, arterial blood gas, lung function, SAA, ChE and CHI3L1 were compared between the two groups, and the occurrence of adverse reactions during treatment was recorded.

    Results

    After treatment, the clinical efficacy of observation group was higher than that of control group, and the improvement time of clinical symptoms was shorter than that of control group (P<0.05). The levels of lung function index and ChE in observation group were higher than those in control group (P<0.05), and the levels of TCM syndrome score, SAA and CHI3L1 were lower than those in control group (P<0.05). No serious adverse reactions occurred in both groups (P>0.05).

    Conclusion

    Yiyuan Qingfei decoction combined with etemicin can effectively improve lung function and serum levels of SAA, ChE and CHI3L1 in the treatment of severe pneumonia with Qi deficiency lung heat syndrome, which is worthy of clinical promotion.

  • Article
  • Baojing TONG , Jie XUE , Xiaofen ZHANG
    doi: 10.13683/j.wph.2024.07.008
    Objective

    To investigate the effect of high-dose folic acid combined with clomiphene citrate on obese patients with polycystic ovary syndrome (PCOS).

    Methods

    A total of 180 obese PCOS patients admitted to our hospital from January 2021 to January 2022 were divided into control group (clomiphene citrate) and study group (clomiphene citrate+folic acid) by random number table method, 90 cases in each group, and treated for 3 menstrual cycles. The clinical efficacy, sex hormone indexes, changes in glucose metabolism, lipid metabolism and the incidence of adverse reactions were compared between the two groups.

    Results

    Compared with the control group, the total effective rate of the study group was significantly increased (P<0.05). After treatment, body mass index, testosterone, luteinizing hormone, follicle-stimulating hormone, fasting blood glucose, fasting insulin, triacylglycerol, total cholesterol and low density lipoprotein of all the patients were decreased compared with before treatment, while estradiol and high density lipoprotein were significantly increased, and the reduction was more obvious in the study group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    High-dose folic acid combined with clomiphene citrate is effective in the treatment of obese PCOS, which can reduce the body mass of patients, improve the levels of sex hormones, glucose metabolism and lipid metabolism, with good safety.

  • Article
  • Zhijuan TAN , Jinying JIA , Zengjian ZHANG
    doi: 10.13683/j.wph.2024.07.009
    Objective

    To investigate the effect of tonifying deficiency and nourishing stomach decoction combined with omeprazole (OME) in the treatment of chronic atrophic gastritis (CAG) and its effect on epidermal growth factor (EGF), motilin (MTL) and soluble interleukin-2 receptor (sIL-2R) levels.

    Methods

    A total of 109 patients with CAG in our hospital from January 2021 to January 2023 were selected and divided into the experimental group (OME+tonifying deficiency and nourishing stomach decoction, n=55) and the control group (OME, n=54) by random number table method. The clinical efficacy, EGF, MTL, sIL-2R, gastrin (GAS), pepsinogen (PG), traditional Chinese medicine symptom score and occurrence of adverse reactions were compared between the two groups after corresponding treatment.

    Results

    After treatment, the total effective rate of experimental group was higher than that of control group (87.27% vs 70.37%, P<0.05). The levels of EGF, GAS and PG in both groups were higher than before (P<0.05), and the levels in experimental group were more significantly higher than those in control group (P<0.05). The levels of sIL-2R and MTL in both groups were lower than before (P<0.05), and the levels in experimental group were more significantly lower than those in control group (P<0.05). The scores of epigastric pain, belching, distension and noisy pantothenic acid in both groups were significantly decreased (P<0.05), and the scores in experimental group were more significantly decreased than those in control group (P<0.05). During treatment, the adverse reactions mainly included loss of appetite, lethargy, nausea and vomiting, but there was no significant difference in incidence between the two groups (P>0.05).

    Conclusion

    Tonifying deficiency and nourishing stomach decoction combined with OME has better efficacy in CAG, which can effectively improve EGF level, reduce MTL and sIL-2R levels, improve clinical symptoms and have good safety.

  • Article
  • Li KUAI , Fanlingzi SHEN , Xiuqi ZHANG , Shenshen GAO , Bin LI , Ruiping WANG
    doi: 10.13683/j.wph.2024.07.010
    Objective

    To incestigate the current status, efficacy and influencing factors of drug therapy for psoriasis patients in Shanghai.

    Method

    An epidemiological observational study was conducted which enrolled 560 psoriasis patients in two hospitals from January 2022 to December 2022. Information on smoking, alcohol consumption, chronic comorbidities, and clinical evaluation of skin lesions were collected based on a questionnaire survey. Follow-up was conducted at 4 and 8 weeks after treatment to evaluate the efficacy and influencing factors of drug therapy.

    Results

    The average age of all patients was (48.4±15.1) years old. The rates of smoking, alcohol consumption and chronic comorbidities were 43.8%, 25.4%, and 53.9%, respectively. The proportion of patients receiving acitretin, methotrexate, narrow band ultraviolet B (NB-UVB) phototherapy, benvitimod and biological agent therapy were 13.2%, 19.3%, 16.8%, 4.8% and 45.9%, respectively. After deducting other influencing factors, patients receiving NB-UVB phototherapy [OR=2.29, 95% confidence interval (CI): 1.01~5.18], benvitimod (OR=4.24, 95%CI: 1.37~13.15), and biological agent therapy (OR=12.55, 95%CI: 5.93~26.57) for 8-week had a higher PASI75 achievement rate for psoriasis.

    Conclusion

    Risk factors such as smoking, alcohol consumption and chronic comorbidities are closely related to the efficacy of psoriasis. It is recommended to strengthen the promote a healthy lifestyle in psoriasis patients, quit smoking and limit alcohol consumption, reduce the incidence of psoriasis comorbidities, which is important for the treatment and prognosis of psoriasis.

  • Article
  • Xueyan QIN , Xiaotian XIE
    doi: 10.13683/j.wph.2024.07.011
    Objective

    To explore the clinical manifestations and genotype characteristics of Diamond-Blackfan anemia (DBA) caused by mutations in the ribosomal protein L35A (RPL35A) gene (RPL35A-DBA) in children.

    Method

    Relevant literature on pediatric RPL35A-DBA with relatively complete data in the past 15 years at home and abroad was collected to summarize, compare, and analyze the clinical manifestations, gene sequencing results, and drug efficacy of these cases.

    Result

    A total of 50 cases of RPL35A-DBA in children were collected. The main characteristics of pediatric RPL35A-DBA were as follows. Age and gender: 90% of cases started within 1 year old, with a median onset age of 3 months. The diagnosis age was relatively late, with an average of 2 years old. There was no significant difference in the incidence rate between men and women (P>0.05). Hematopoietic disorders: the main manifestation was moderate to severe anemia, with 54% (27/50) relied on blood transfusion, and most (68%, 34/50) accompanied by granulocytopenia, while platelet levels were normal. Gene mutation: the phenotype of the large deletion type (n=22) was more severe than that of the non-large deletion type (n=28), and the incidence of hematopoietic system abnormalities, immune deficiency, intellectual disability, craniofacial deformity, and skeletal dysplasia were significantly increased (P<0.05). Drug therapy: the main treatment drug was glucocorticoid (GC), and component blood transfusion combined with iron removal therapy should be given as appropriate. If necessary, allogeneic hematopoietic stem cell transplantation (allo-HSCT) should be performed.

    Conclusion

    RPL35A-DBA is more common in children with early onset after birth, and the degree of gene deficiency is closely related to the severity of clinical manifestations. For some cases, GC is effective, but the minimum maintenance dose is required, and allo-HSCT should be performed for severe cases. For suspected cases of RPL35A-DBA, timely genetic testing should be conducted to aid in early diagnosis and effective clinical intervention.

  • Article
  • Li QIN , Jiayi ZHAI , Libin GE
    doi: 10.13683/j.wph.2024.07.012
    Objective

    To analyze the present situation of blood pressure of preschool children and discuss its influencing factors.

    Methods

    A total of 497 preschoolers from two kindergartens in Jiading District of Shanghai were included. Gender, age, height, weight and other information were collected, sitting blood pressure and heart rate were measured three times, and relevant indexes of urine routine were analyzed. With reference to the 2018 edition of China Hypertension Guidelines, the blood pressure level was graded according to the average value of the second and third blood pressure. SAS 9.4 software was used to analyze the data.

    Results

    A total of 497 preschool children were enrolled, with an average age of (4.5±0.8) years. 26.96% of the children were overweight or obese. 7.44% of the children with high normal blood pressure, 7.04% of the children with grade 1 hypertension, 0.4% of the children with grade 2 hypertension, 1.2% of the children had a positive urinary albumin-to-creatinine ratio. Orderly multivariate logistic regression analysis showed that overweight and obesity [odds ratio (OR)=3.133, 95% confidence interval (CI): 1.56~6.31] and increased heart rate (OR=1.09, 95%CI: 1.06~1.11) were the influening factors of hypertension in preschool children (P<0.05).

    Conclusion

    Overweight, obesity and increased heart rate are risk factors for hypertension in preschool children. It is recommended to monitor body mass index, blood pressure and heart rate of preschool children regularly every year, and conduct classified health management according to relevant conditions.

  • Article
  • Juan GE , Jingjing WANG , Hongqun WANG
    doi: 10.13683/j.wph.2024.07.013
    Objective

    To investigate the predictive value of serum albumin (ALB) level and score for neonatal acute physiology with perinatal extension (SNAPPE)-Ⅱin infection and prognosis of premature infants.

    Methods

    The infected premature infants were selected as the infected group (n=46) and the control group without infected infants (n=36). The value of ALB, SNAPPE-Ⅱ and their combination in predicting the infection of preterm infants in two groups were compared and analyzed.

    Results

    There were significant differences in hospitalization time, oxygen inhalation time, mechanical ventilation time, non-invasive positive pressure ventilation time, and intravenous nutrition time between the two groups (P<0.05). The differences in ALB and SNAPPE-Ⅱ between the two groups were statistically significant (P<0.05). The results of multivariate unconditional logistic analysis showed that hospitalization time, oxygen inhalation time, mechanical ventilation time, non-invasive positive pressure ventilation time, intravenous nutrition time, and SNAPPE-Ⅱ were independent risk factors for premature infant infection (P<0.05), and ALB level was an independent protective factor for premature infant infection (P<0.05). receiver operating characteristic curve analysis of SNAPPE-Ⅱ for premature infant infection showed that the area under the curve of ALB, SNAPPE-Ⅱ, and their combination for diagnosing premature infant infection were 0.761, 0.738, and 0.893, respectively, the combination of the two showed the highest efficacy.

    Conclusion

    Serum ALB and SNAPPE-Ⅱ have better value in prognosis diagnosis of infection in premature infants, and their combined effect is better, which can guide rational and timely antimicrobial therapy and improve prognosis.

  • Article
  • Jianhong ZHANG , Sheng CAO , Yinzhen CAO , Xinhua LI , Xiaochun YE
    doi: 10.13683/j.wph.2024.07.014
  • Review
  • Xiaodong ZHAO , Huaying CHEN , Tao CHEN , Yanmei ZHANG , Hua LI
    doi: 10.13683/j.wph.2024.07.015

    In 2018, the U.S. FDA approved the first small interfering RNA (siRNA) drug Patisiran, marking a brand-new era for RNA interference therapy. siRNA has developed rapidly in recent years due to its unique drug-forming advantages. Five siRNA drugs have been approved for marketing by the FDA. However, there are still many problems in targeting and efficacy in therapeutic applications. In order to develop new products with more potential value, it is necessary to deeply explore the current status of siRNA drug discovery and development. This article reviewed the advantages and hindrances of siRNA in drug discovery, focused on the research progress of chemical modification strategies and delivery systems of siRNA drugs, in order to provide a reference for the subsequent research.

  • Review
  • Zhilong LAN , Lei WANG , Song ZHANG , Zhihui LI , Junlong WANG , Na NI
    doi: 10.13683/j.wph.2024.07.016

    Immunoglobulin is recognized to be used for the treatment of various diseases, not only because it can serve as an alternative therapy against infections, but also because of its immunomodulatory effects. Appropriate use of immunoglobulins can save lives. However, its route of administration may lead to many adverse events and potential other adverse consequences. At present, intravenous immunoglobulin is the main clinical use in China, but there are more adverse events in the process of clinical use, and the patient compliance is not high. Due to this unmet clinical need, subcutaneous immunoglobulin (SCIg) has been developed abroad, which has been used in multiple clinical indications. However, SCIg in China is still in the early stage of exploration and research and development. Faced with the huge clinical needs in China, domestic blood product research and development companies have been encouraged to accelerate the research and development of SCIg drugs of different specifications and different indications to meet the treatment needs of domestic patients. This article reviewed the latest clinical research progress of SCIg in the treatment of primary immunodeficiency diseases, autoimmune neuromuscular diseases and other rare diseases, in order to provide new research and development ideas and suggestions for blood product research and development enterprises in China.

News